Drugs / RO7669330
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06961370 | Jul 2025 → Jan 2027 expected | age-related macular degeneration, diffuse secondary choroid atrophy | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7669330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961370 ↗ |
| Route | Intravitreal | “RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.” NCT06961370 ↗ |